BTK and B-cell chronic lymphocytic leukemia: It is now evident that CLL patients express significantly higher numbers of EVs and CD19-expressing EVs, which decrease significantly upon treatment with Bruton’s tyrosine kinase (BTK) or phosphoinositide 3-kinase (PI3K) inhibitors.